THE WOODLANDS, Texas, March 4, 2026
Autonomix Medical, Inc. announced that its novel transvascular peripheral radiofrequency (RF) nerve neurolysis technology has been selected as a Top Abstract for presentation at the Cardiovascular Research Technologies (CRT) 2026 conference. The company will present clinical feasibility and early outcome data demonstrating the potential of its catheter-based system to selectively disrupt peripheral nerve signals using a transvascular RF ablation technique, marking an important step in the development of precision nerve-targeted therapies for conditions such as chronic pain, hypertension, and cancer-related pain.
Novel RF Neurolysis Technique Demonstrates Early Feasibility
The selected abstract, titled “Novel Technique for Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility and Outcomes,” will be presented during the Top Abstract session at CRT 2026, a leading global meeting focused on innovations in interventional cardiovascular medicine. The research highlights the clinical feasibility and early outcomes of a novel RF-based method designed to selectively disrupt peripheral nerve activity via a minimally invasive transvascular approach.
Unlike conventional nerve ablation techniques that rely on direct tissue targeting, the Autonomix platform introduces a catheter-based approach capable of identifying and targeting specific neural signals within the vascular system. By using radiofrequency energy to modulate peripheral nerve activity, the technology aims to deliver highly precise neuromodulation while reducing unintended damage to surrounding tissues.
Early clinical observations suggest that this targeted approach may enable more accurate identification and treatment of disease-related nerve signals, potentially improving therapeutic outcomes compared with traditional nerve ablation procedures.
Advertisement
Precision Nerve Mapping Technology Enables Targeted Treatment
At the core of Autonomix’s platform is a catheter-based microchip sensing array capable of detecting and differentiating neural signals with greater sensitivity than existing technologies. This capability could allow physicians to map nerve activity in real time and identify specific nerves contributing to disease symptoms before delivering targeted treatment.
Such precision could be particularly valuable for conditions in which abnormal peripheral nerve signaling drives disease progression or severe symptoms, including chronic pain disorders, hypertension, and cancer-related pain syndromes.
The company is initially focusing its clinical development efforts on pain associated with pancreatic cancer, a condition known for causing severe and difficult-to-manage pain. By targeting nerve signals responsible for transmitting pain signals, the technology could potentially provide a more effective and durable treatment option for patients who currently have limited therapeutic alternatives.
CRT 2026 Recognition Highlights Scientific Innovation
The CRT conference is widely recognized as one of the most influential educational forums for interventional cardiology and cardiovascular device innovation. Abstracts selected for podium presentation in the Top Abstract session represent the highest-ranked submissions based on scientific merit, clinical innovation, and potential impact on patient care.
Autonomix’s selection for this prestigious session underscores the growing interest in precision neuromodulation technologies capable of diagnosing and treating diseases linked to the peripheral nervous system. Investigators believe that the ability to detect and modulate nerve signals through a transvascular approach could open the door to new therapeutic applications across multiple medical specialties.
Beyond pain management, the company believes its platform may have applications in cardiology, hypertension treatment, and chronic disease management, where abnormal nerve signaling plays a key role in disease mechanisms.
Expanding the Future of Bioelectronic Medicine
The development of Autonomix’s RF neurolysis technology reflects the broader evolution of bioelectronic medicine and neuromodulation therapies, fields that use targeted electrical or energy-based interventions to treat disease by modulating nerve signals.
By combining advanced signal detection with minimally invasive catheter-based treatment, the platform could enable clinicians to diagnose and treat nerve-related diseases with unprecedented precision.
Although the technology remains investigational and has not yet received regulatory clearance in the United States, researchers believe continued clinical evaluation could help demonstrate its safety and therapeutic value.
As interest in nerve-targeted therapies continues to grow across multiple therapeutic areas, the upcoming CRT 2026 presentation may provide valuable insights into how precision neuromodulation technologies could reshape the treatment of complex diseases driven by abnormal nerve signaling.
z
Source: Autonomix Medical, Inc press release
